Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.13

Mkt cap

467M

Volume

3.3M

High

2.38

P/E Ratio

-3.54

52-wk high

3.40

Low

2.13

Div yield

N/A

52-wk low

1.15

Esperion Therapeutics (NASDAQ:ESPR) has received 4 bullish analyst ratings in the last quarter with an average price target of $15.25, indicating a significant upside from the current price of $0.9199. The average price target has risen by 69.44% over the past month, suggesting a positive outlook from analysts on the stock.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 6:00 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:19 pm

Esperion (NASDAQ:ESPR) presented results from a CLEAR Outcomes analysis at the American Heart Association Scientific Sessions 2023, showing that higher baseline inflammation is linked to an increased risk of cardiovascular events. The study found that bempedoic acid, found in Esperion's products NEXLETOL and NEXLIZET, reduced the vascular inflammatory marker hsCRP by 21.6% in patients, which may differentiate it from other LDL-lowering therapies. These results were also published in the journal Circulation.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 3:31 pm

Needham analyst Serge Belanger has maintained a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) but lowered the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:29 pm

Esperion Therapeutics reported Q3 earnings per share (EPS) of $(0.37), beating the analyst consensus estimate of $(0.43) by 13.95%. This is a 54.32% increase over losses from the same period last year. The company also reported quarterly sales of $33.96 million, beating the analyst consensus estimate of $29.58 million by 14.81%. This is a 78.93% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 11:04 am

Several healthcare stocks experienced significant movement in Monday's after-market session. Unicycive Therapeutics, BioSig Technologies, Amneal Pharmaceuticals, Esperion Therapeutics, GRI Bio, and Blue Water Biotech saw gains, while LumiraDx, SeaStar Medical Holding, CareDx, Vivos Therapeutics, Apollomics, and Sonendo experienced losses.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 9:31 pm

On Tuesday, 132 companies hit new 52-week lows. Among them, Corning (NYSE:GLW) was the largest in terms of market cap, while Wheeler Real Estate IT (NASDAQ:WHLR) was the smallest. Fortress Biotech (NASDAQ:FBIO) saw the largest move with shares plummeting 1350.03%, while Insulet (NASDAQ:PODD) made the biggest bounce back, moving up 0.0% shortly after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 5:09 pm

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included Acorda Therapeutics (ACOR), Vivos Therapeutics (VVOS), Pasithea Therapeutics (KTTA), Enveric Biosciences (ENVB), 60 Degrees (SXTP), and Esperion Therapeutics (ESPR). Losers included MaxCyte (MXCT), Heart Test Laboratories (HSCS), Senti Biosciences (SNTI), Accolade (ACCD), Elutia (ELUT), and PDS Biotechnology (PDSB).

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 9:31 pm

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:31 am

In Wednesday's after-market session, several healthcare stocks saw significant movement. Allarity Therapeutics (NASDAQ:ALLR), Ainos (NASDAQ:AIMD), TC BioPharm (NASDAQ:TCBP), NexGel (NASDAQ:NXGL), Blue Water Biotech (NASDAQ:BWV), and Esperion Therapeutics (NASDAQ:ESPR) all saw increases, with Allarity Therapeutics leading the gainers with a 31.5% increase. On the other hand, Dermata Therapeutics (NASDAQ:DRMA), Genprex (NASDAQ:GNPX), Oncology Institute (NASDAQ:TOI), Axcella Health (NASDAQ:AXLA), Phibro Animal Health (NASDAQ:PAHC), and Brookdale Senior Living (NYSE:BKD) all saw declines, with Dermata Therapeutics leading the losers with a 7.8% decrease.

Portfolio Pulse from Benzinga Insights

August 30, 2023 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.